An Open-label Trial With TMC125 in Patients Who Have Virologically Failed in a DUET Trial (TMC125-C206 or TMC125-C216).
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to evaluate the long-term safety and tolerability of TMC125 200
mg twice daily as part of an antiretroviral therapy including TMC114/rtv and an investigator
selected optimized background in HIV-1 infected patients who have participated in a DUET
trial (TMC125-C206 or TMC125 C216) and have met the definition of virologic failure at Week
24 or later in these trials.